Evidence map›Paper›PMID 39777337›Full record

ArticleFrontiers in oncology2024

PGD2/PTGDR2 signaling pathway affects the self-renewal capacity of gastric cancer stem cells by regulating ATG4B ubiquitination.

Qiang Zhang, HengJin Tian, Kunpeng Ge, FeiFan Wang, PeiYao Gao, AMin Chen, Lulu Wang, YanMing Zhao, Chaoqun Lian, FengChao Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Qiang Zhang *Department of Clinical Laboratory, The First Affiliated Hospital of Bengbu Medical University, Bengbu, China.
HengJin Tian *Department of Clinical Laboratory, The First Affiliated Hospital of Bengbu Medical University, Bengbu, China.
Kunpeng GeKey Laboratory of Cancer Research and Clinical Laboratory Diagnosis, Bengbu Medical University, Bengbu, China.
FeiFan WangDepartment of Blood Transfusion, The First Affiliated Hospital of Naval Medical University, Shanghai, China.
PeiYao GaoKey Laboratory of Cancer Research and Clinical Laboratory Diagnosis, Bengbu Medical University, Bengbu, China.
AMin ChenDepartment of Clinical Laboratory, The First Affiliated Hospital of Bengbu Medical University, Bengbu, China.
Lulu WangDepartment of Clinical Laboratory, The First Affiliated Hospital of Bengbu Medical University, Bengbu, China.
YanMing ZhaoDepartment of Clinical Laboratory, The Second People's Hospital of Bengbu, Bengbu, China.
Chaoqun LianKey Laboratory of Cancer Research and Clinical Laboratory Diagnosis, Bengbu Medical University, Bengbu, China.
FengChao WangDepartment of Clinical Laboratory, The First Affiliated Hospital of Bengbu Medical University, Bengbu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Prostaglandin D2 (PGD2) inhibits the development of different malignant tumors; however, the underlying mechanism of inhibiting tumor development is not yet clear. This study aimed to elucidate how PGD2 inhibits the stemness of gastric cancer stem cells (GCSCs) Methods: In this study, GCSCs were enriched Results: The results indicated that PGD2 induced LC3I/LC3II conversion in GCSCs to activate autophagy, while PGD2 promoted the expression of PTGDR2, thereby further activating autophagy. Furthermore, PTGDR2 competes with ATG4B for binding with E3 ligase RNF5 (also known as RMA1) to promote autophagy protein ATG4B expression. Moreover, PTGDR2 knockdown blocked the activation of autophagy by PGD2 and the level of ATG4B ubiquitination in GCSCs. Conclusions: In summary, it was elucidated that the PGD2/PTGDR2 signaling cascade affects GCSCs stemness by regulating autophagy, suggesting that the PGD2/PTGDR2 signaling pathway could serve as a novel target for cancer therapy.

Indexed as

autophagycancer stem cellsgastric cancerPTGDR2ubiquitination

Identifiers

PMID39777337
PMCPMC11703842

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.